Low-dose corticosteroids were employed as first-line treatment to manage CRS in patients with B-ALL undergoing CD19- or CD22-CAR-T cell therapy, encompassing both children and adults; however, a comparison of survival between the two groups was not conducted. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.